Novo Nordisk to invest billions in U.S. factory

Due to the high demand for its diabetes medication, Ozempic, and the obesity treatment, Wegovy, Novo Nordisk is investing approximately 29 billion DKK (4.1 billion USD) to double the production facility area in Clayton, North Carolina. The investment will be used to construct an additional filling plant covering 130,000 square meters. Novo Nordisk’s CEO, Lars Fruergaard Jørgensen, emphasizes the move to meet the increasing global demand for their life-changing medications. The expansion is expected to create 1,000 permanent jobs in addition to the existing 2,500 positions. Eco-friendly measures, including solar panels and water-saving installations, are integral to the new buildings. The preparation for construction has begun, with completion expected between 2027 to 2029. Additionally, Novo Nordisk plans to invest 45 billion DKK in 2024 for production facilities and has recently acquired three filling factories in the USA, Belgium, and Italy, while also expanding production in Denmark.